他汀类药物可降低未破裂椎基底动脉夹层动脉瘤血管壁MRI上的壁强化:一项随机对照试验
这项开放标签随机对照试验纳入40例未破裂椎基底动脉夹层动脉瘤患者,1:1分为每日20 mg阿托伐他汀组和对照组,评估6个月治疗对血管壁MRI壁强化的影响。结果显示阿托伐他汀组壁强化指数变化为-0.3、对照组为0.1(P < .001),壁强化体积率变化为-15.1%、对照组为5.3%(P < .001),且炎症相关循环生物标志物改善、壁内血肿进展减缓(304.0 mm3 vs 100.3 mm3;P = .006),两组动脉瘤大小均无变化。
要点
- 阿托伐他汀组6个月壁强化指数变化-0.3,对照组0.1(P < .001)。
- 阿托伐他汀组壁强化体积率变化-15.1%,对照组5.3%(P < .001)。
- 阿托伐他汀组壁内血肿进展减缓(304.0 mm3 vs 100.3 mm3;P = .006)。
核心结论
- 与对照组相比,阿托伐他汀使用降低了未破裂椎基底动脉夹层动脉瘤在血管壁MRI上的壁强化。
研究设计与样本
- 开放标签随机对照试验,2021年7月至2023年1月纳入40例未破裂椎基底动脉夹层动脉瘤患者,1:1随机分为每日20 mg阿托伐他汀组或对照组,基线及6个月随访行血管壁MRI,主要终点为定量壁强化指数和三维壁强化体积率的变化。
关键影像表现/征象
- 阿托伐他汀组6个月时动脉瘤壁的壁强化指数和壁强化体积率均较基线下降。
- 壁强化指数变化:阿托伐他汀组-0.3 vs 对照组0.1(P < .001)。
- 壁强化体积率变化:阿托伐他汀组-15.1% vs 对照组5.3%(P < .001)。
- 壁内血肿进展:阿托伐他汀组304.0 mm3 vs 对照组100.3 mm3(P = .006),阿托伐他汀组进展减缓。
- 两组均未检测到动脉瘤大小变化。
诊断标准与关键数值
- 主要终点为定量壁强化指数和三维壁强化体积率的变化。
- 壁强化指数变化:阿托伐他汀组-0.3 vs 对照组0.1(P < .001)。
- 壁强化体积率变化:阿托伐他汀组-15.1% vs 对照组5.3%(P < .001)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Vertebrobasilar dissecting aneurysms (VBDAs) are important causes of stroke. Aneurysm wall enhancement at vessel wall (VW) MRI is a marker of inflammation. Previous studies have shown that statins may reduce inflammation in intracranial saccular aneurysms, but their effect on VBDAs remains unknown. Purpose To evaluate the effect of 6-month atorvastatin treatment on VBDA wall enhancement on VW MRI scans. Materials and Methods Participants with unruptured VBDAs were enrolled in this open-label, randomized controlled trial from July 2021 to January 2023 and randomized 1:1 to the daily 20 mg atorvastatin group or control group. VBDAs were imaged with VW MRI at baseline and at the 6-month follow-up. The primary end point was the change in aneurysm wall enhancement measured by the quantitative wall enhancement index (WEI) and three-dimensional wall enhancement volume rate (WEVR). The secondary outcomes were changes in aneurysm size or morphology and inflammation-related circulating biomarkers. All outcome analyses were performed using appropriate tests for categorical and continuous variables. Results A total of 40 participants were included (mean age, 52 years ± 11 [SD]; 34 men). In the statin group, both the WEI and WEVR of the aneurysm wall decreased at 6 months compared with those at baseline. The change in WEI was -0.3 in the statin group but 0.1 in the control group (P < .001). Similarly, the change in WEVR was -15.1% in the statin group but 5.3% in the control group (P < .001). Additionally, the circulating plasma levels of C-reactive protein, tumor necrosis factor α, interleukin-6, and interleukin-1β improved in the atorvastatin group compared with the control group (all P < .05). The atorvastatin group also showed slowed progression of intramural hematoma (304.0 mm3 vs 100.3 mm3; P = .006). No change in aneurysm size was detected in both groups. Conclusion Atorvastatin use decreased VBDA wall enhancement on VW MRI scans compared with the control group. ClinicalTrials.gov Identifier: NCT04943783 © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Mohajer and Chernyak in this issue.
引用
- Zhang Y, Wang C, Dong L, et al. Statins Reduce Wall Enhancement at Vessel Wall MRI in Unruptured Vertebrobasilar Dissecting Aneurysms: A Randomized Controlled Trial. Radiology. 2025. PMID: 41432563. doi:10.1148/radiol.242806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。